Much work has been done to identify susceptibility genes in schizophrenia and bipolar disorder. Several well-established linkages have emerged in schizophrenia. Strongly supported regions are 6p24–22, 1q21–22, and 13q32–34, while other promising regions include 8p21–22, 6q16–25, 22q11–12, 5q21–q33, 10p15–p11, and 1q42. Genomic regions of interest in bipolar disorder include 6q16–q22, 12q23–q24, and regions of 9p22–p21, 10q21–q22, 14q24–q32, 13q32–q34, 22q11–q22, and chromosome 18. Recently, specific genes or loci have been implicated in both disorders and, crucially, replicated. Current evidence supports NRG1, D10N18P1, DISC1, DAOA(G72), DAO, and RGS4 as schizophrenia susceptibility loci. For bipolar disorder the strongest evidence supports DAOA(G72) and **BDNF**. Increasing evidence suggests an overlap in genetic susceptibility across the traditional classification systems that dichotomised psychotic disorders into schizophrenia or bipolar disorder, most notably with association findings at DAOA(G72), DISC1, and NRG1. Future identification of psychosis susceptibility genes will have a major impact on our understanding of disease pathophysiology and will lead to changes in classification and the clinical practice of psychiatry.

See end of article for authors’ affiliations

Correspondence to: Nick Craddock, Department of Psychological Medicine, The Henry Wellcome Building for Biomedical Research, Academic Avenue, Wales School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK; craddockn@cardiff.ac.uk

Received 5 January 2005 Accepted for publication 5 January 2005

---

**SCHIZOPHRENIA**

**Genetic epidemiology**

Schizophrenia has been subjected to detailed genetic epidemiological investigation. The results of numerous family, twin, and adoption studies show conclusively that risk of illness is increased among the relatives of affected individuals and that this is the result largely of genes rather than shared environment. In the children and siblings of individuals with schizophrenia, the increase in risk is around 10-fold, and somewhat less than this in parents. The latter finding is probably explained by a reduction in the reproductive opportunities, drive, and possibly fertility of affected individuals. Five recent systematically ascertained studies using modern diagnostic criteria report monozygotic (MZ) concordances estimated at 41–65% compared with dizygotic (DZ) concordances of 0–28%, resulting in an estimated broad heritability of 85%.

While the twin and adoption literature leave little doubt that genes are important, they also point to the importance of environmental factors, since the concordance for schizophrenia in MZ twins is typically around 50% and heritability estimates are less than 100%. Moreover, we should also note that liability resulting from gene-environment interaction tends to be attributed to heritability in most genetic epidemiological studies.

It is clear from genetic epidemiology that the mode of transmission is complex. The number of susceptibility loci, the disease risk conferred by each locus, the extent of genetic heterogeneity, and the degree of interaction among loci all remain unknown. Risch has calculated that the data are incompatible with the existence of any single locus conferring a relative risk in siblings...
that the number of loci meeting the aggregate criteria for significance was much greater than the number of loci expected by chance (p<0.001). Support was also obtained for regions on chromosomes 9q, 3p, 11q, 6p, 1q, 22q, 8p, 20q, and 14p. Thus the 8p and 22q regions were supported by both meta-analyses but eight other regions were supported by only one. Furthermore, the region most strongly supported by the Lewis et al analysis, that on chromosome 2q, is not one that has received strong support previously, but it is now clearly worthy of further investigation.

Previously, the economics and practicalities of hunting a susceptibility gene within a linked chromosomal region dictated that one should have virtually definitive evidence that the linkage was a true positive. With recent improvements in our knowledge of genome anatomy and in genome analysis technology, the task of positional cloning has been transformed, and, in our view, favours bolder endeavours predicated on less stringent evidence. How much evidence will be dictated largely by research funding bodies, but it seems not unreasonable to the authors to pursue a locus based upon a true type I error rate of 0.05 even in the absence of replication, with the proviso that the error rate has been rigorously assessed by simulation and allows for examination of multiple models. For many of the above regions, such studies are underway. While some of the above loci will inevitably be false positives, many will not and it is likely that several genes cloned by positional approaches will be claimed in the next few years. In the next section, we discuss those genes that have been claimed so far.

Candidate gene findings in schizophrenia

Functional candidate genes

Most of the recent findings of interest in schizophrenia have emerged from positional cloning studies, but there is also a large schizophrenia functional candidate gene literature which we will only touch on in this review. In the main, the findings have either not been replicated or have seemed so unconvincing that no attempts to do so have been made. However, meta-analyses suggest that the dopamine receptors DRD3, DRD2, and the serotonergic receptor HTR2A might confer risk, albeit with extremely small (<1.2) effect sizes. We should, however, remember that if the putative associations are the result of linkage disequilibrium between the assayed markers and the true susceptibility variant, it is possible that the latter might contribute somewhat greater effects, depending upon the degree of linkage disequilibrium (LD) between the two. Among the recent claims, reports of association between GRM3 (the gene encoding metabotropic glutamate receptor type 3) and schizophrenia are among the more interesting, although in our view, the genetic data

Figure 1  Chromosome ideograms showing locations of genome-wide significant linkages in schizophrenia and bipolar disorder. Asterisks mark the locations of chromosomal abnormalities associated with schizophrenia.
remain weak. Further study of GRM3 in particular and the glutamatergic system in general is warranted.

Positional candidate genes
Several detailed mapping studies of linked regions have implicated specific genes. The quality of the data has been variable and a number of putative susceptibility genes have yet to be clearly replicated. Here we focus on the genes where, at the time of writing, there are published follow up studies, or where we are aware of unpublished data that allow us to make a judgement about whether the gene is likely to be a true positive.

Dysbindin (DTNBP1)
Evidence implicating dystrobrevin binding protein 1 (DTNBP1), also known as dysbindin, in schizophrenia was first reported by Straub et al., who undertook association mapping across the linkage region on chromosome 6p22.3. Support for association rapidly followed from a largely German sample and in two large samples, one case-control from the UK and Ireland and the other a parent-proband from Bulgaria studied by our own group. Although there have also been some studies in which no association was found, significant associations have now been published in 10 samples including an initially negative Irish sample, when one additional marker that defined the risk haplotype in our own UK sample was genotyped. Thus, the evidence in favour of DTNBP1 as a susceptibility gene for schizophrenia is strong. However, there are inconsistencies between the specific risk alleles and haplotypes between studies suggesting the presence of multiple susceptibility and protective alleles, or that a single susceptibility allele is carried on a remarkable diversity of haplotypes even in closely related populations. As yet, no causative variant has been identified, but the absence of associated non-synonymous alleles suggests that disease susceptibility may depend upon variation affecting mRNA expression. This is indirectly supported by evidence for as yet unknown cis-acting polymorphisms affecting DTNBP1 expression in human brain, and more directly by two recent studies showing reduced levels of expression of the mRNA and protein in postmortem brain samples from patients with schizophrenia.

Although its functions are largely unknown but probably many, there is evidence that variation in DTNBP1 might influence risk of schizophrenia through effects on pre-synaptic glutamate function.

Neuregulin 1 (NRG1)
NRG1 was first implicated in schizophrenia in the Icelandic population after LD mapping across 8p21–22 revealed association between schizophrenia and a multi-marker haplotype at the 5’ end of NRG1. Strong evidence for association with the same haplotype was subsequently found in a large sample from Scotland, with considerably weaker support in our own UK sample. Further positive findings have emerged from Irish, Chinese, Bulgarian (Kirov et al., unpublished data), and South African samples. However, some negative findings have also been reported. Only the two deCODE studies and our own UK study have implicated the specific Icelandic haplotype, perhaps reflecting differences in the LD structure across NRG1 in European and Asian samples.

NRG1 encodes many mRNA species and proteins. Despite detailed resequencing, specific susceptibility variants have not been identified, but the Icelandic haplotype points to the 5’ end of the gene, once again suggesting that altered expression or perhaps mRNA splicing might be involved. It is even formally possible at this stage that NRG1 is not the susceptibility gene, as intron 1 contains another expressed sequence whose function is unknown. However, in so far as it is possible to model schizophrenia in animals, behavioural analyses of NRG1 hypomorphic mice support the view that the association is related to altered NRG1 function or expression, a hypothesis supported by the observation of alteration in the ratios of NRG1 mRNA species in schizophrenic brain. Just as for DTNBP1, the mechanisms by which altered NRG1 function might lead to schizophrenia are unclear. Mediation of glutamatergic mechanisms may be involved; however, NRG1 is thought to encode around 15 proteins with a diverse range of functions in the brain, including cell-cell signalling, ErbB receptor interactions, axon guidance, synaptogenesis, glial differentiation, myelinisation, and neurotransmission. Any of these could potentially influence susceptibility to schizophrenia.

D-Amino-acid oxidase (DAO) and D-amino-acid oxidase activator (DAOA)
Chumakov and colleagues undertook association mapping in the linkage region on chromosome 13q22–34. They found associations in French Canadian and Russian populations in markers around two novel genes, G72 and G30, which are overlapping but transcribed in opposite directions. G72 is a primate-specific gene expressed in the caudate and amygdala. Using yeast two-hybrid analysis, evidence for a functional interaction was found between G72 and D-amino-acid oxidase (DAO). DAO is expressed in human brain where it oxidises D-serine, a potent activator of NMDA glutamate receptor. Co-incubation of G72 and DAO in vitro revealed a functional interaction with G72 enhancing the activity of DAO. Consequently, G72 has now been named D-amino-acid oxidase activator (DAOA). In the same study, DAO polymorphisms were shown to be associated with schizophrenia in one of the samples, and analysis of DAOA and DAO variants revealed modest evidence for a statistical interaction between the loci and disease risk. Given the three levels of interaction, the authors concluded that both genes influence risk of schizophrenia through a similar pathway, and that this effect is likely to be mediated through altered NMDA receptor function.

Associations between DAOA and schizophrenia have subsequently been reported in samples from Germany, China, Ashkenazi Jews, and both US and South Africa as well as we do find evidence for an interactive effect on risk of disease between the same markers at each locus as did Chumakov and colleagues.

Regulator of G-protein signalling 4 (RGS4)
RGS4 maps to the putative linkage region on chromosome 1q22, but it was targeted for genetic analysis following a microarray based gene expression study in which decreased RGS4 expression was found in schizophrenic postmortem brain. Independent evidence for association between schizophrenia and a haplotype at the 5’ end of the gene was found in two samples from the USA, and while not providing significant evidence alone, inclusion of a sample from India added to the overall level of support. Positive findings have
subsequently been reported by several other groups, but the level of support in each has been modest and the pattern of association differs between samples. RGS4 is a negative regulator of G protein coupled receptors. The relationship between RGS molecules and receptor function is a promiscuous one, but of possible interest to schizophrenia. There is evidence that RGS4 modulates activity at certain serotoninergic and metabotropic glutamatergic receptors, while its own expression is modulated by dopaminergic transmission. Moreover, RGS4 interacts with ErbB3, which may be of relevance as ErbB3 is a neuregulin 1 receptor whose expression is down regulated in schizophrenic brains.

Others

Finally, association analysis in single studies of CAPON (C-terminal PDZ domain ligand of neuronal nitric oxide synthase), PPP3CC (protein phosphatase 3, catalytic subunit), and TRAR4 (trace amine receptor 4), which map, respectively, to the 1q22, 8p21.3, and 6q23.2 linkage regions, has suggested these as possible susceptibility genes. As discussed in the original articles, each of these genes can be plausibly related to the pathogenesis of schizophrenia, but at the time of writing we are not aware of any replication data to support these hypotheses.

Chromosomal abnormalities

There have been numerous reports of associations between schizophrenia and chromosomal abnormalities but with two exceptions none provides convincing evidence for the location of a susceptibility gene.

22q11

Several studies have shown that adults with 22q11 deletions have a high risk for schizophrenia, with the largest study of adult patients to date (n = 50) estimating this at 24%. The deletion cannot account for a high proportion of schizophrenic cases, but reports of linkage to 22q11 suggest that variants in genes mapping to this region might contribute to more typical cases. Current candidates include catechol-O-methyltransferase (COMT), proline dehydrogenase (PRODH), and zinc finger- and DHHC domain-containing protein 8 (ZDHHC8).

COMT has been intensively studied because of its key role in dopamine catabolism. Most studies have focussed upon a valine to methionine change at codon 158 of the brain predominant membrane-bound form of COMT (MB-COMT) and codon 108 of the soluble form (S-COMT). The valine allele confers higher activity and thermolability to both forms of COMT and has been fairly consistently associated with reduced performance in tests of frontal lobe function.

The results in schizophrenia have been mixed, with a recent meta-analysis reporting no overall evidence for association with the valine allele. Since the preparation of the COMT meta-analysis, as in an earlier study, four studies have found stronger evidence for association between haplotypes at COMT than for the Val/Met locus alone. However, we have been unable to find evidence for association between the single nucleotide polymorphisms (SNPs) or haplotypes that were positive in three of the studies, including the Val/Met polymorphism, in a study of more than 2800 individuals, including almost 1200 with schizophrenia. Moreover, it is difficult to reconcile the stronger evidence for association with haplotypes at COMT with the observation that COMT activity, at least in peripheral tissues, is largely dictated by the Val/Met locus, a finding that may also be true in brain. Thus, while the picture is confused, we consider that the evidence does not support a simple role for Val/Met 158 in susceptibility to schizophrenia, although a small effect on susceptibility cannot be excluded, nor can a role in phenotype modification.

However, it remains a possibility that variation elsewhere in COMT, or in a neighbouring gene such as ARVCF, confers susceptibility. PRODH is also located at 22q11 and is another functional candidate gene given that a mouse loss of function mutant exhibits behavioural abnormalities in sensorimotor gating that are analogous to those observed in schizophrenic subjects, and because proline dehydrogenase influences the availability of glutamate. In addition, a heterozygous deletion of the entire PRODH gene was found in a family including two schizophrenic subjects, and two heterozygous PRODH missense variants were detected in three of 63 schizophrenic patients studied by Jacquet et al. Evidence in favour of association between PRODH and schizophrenia has been reported by Liu and colleagues and by Li and colleagues. We have been unable to replicate either of these findings in large case-control and family based association samples and unpublished data. Moreover, we and others have also found that the missense mutations reported by Liu and colleagues are no more common in schizophrenic cases than controls, while in a very large sample of Japanese subjects, PRODH deletions were not associated with schizophrenia. Thus the case for PRODH as a susceptibility gene for schizophrenia does not seem strong to us. However, intriguingly, the study of Jacquet and colleagues while failing to find association with schizophrenia (or bipolar disorder), did report association between hyperprolinaemia and schizoaffective disorder. This may suggest that PRODH may have some role in phenotype modification although this conclusion is highly tentative as the results of this study are based on a small sample and are not significant after correction for multiple testing.

Finally, there is weak genetic evidence that an SNP in ZDHHC8, a gene which encodes a putative transmembrane palmitoyl transferase, directly confers susceptibility to schizophrenia but only in females. The findings were particularly interesting in that study because the weak genetic evidence was bolstered by evidence that the associated SNP was functional and that sexually dimorphic effects could be seen in ZDHHC8 knockout mice, with only female mice exhibiting the phenotypes used to model schizophrenia. However, while providing supportive evidence for association, Chen and colleagues found that the associated allele was the opposite to that of Mukai and colleagues, thus undermining the functional data, while also showing the effect apparently in a gender non-selective fashion, thus undermining the mouse model analogy. The only other study we are aware of is unpublished data from ourselves and others based upon almost 2000 schizophrenic subjects that do not support the finding. The findings are at present inconclusive, but given the large sample sizes studied by ourselves and the German group, together with the failure of the Chinese group to replicate the original findings in two key respects, we consider the balance of evidence for this gene still favours the null hypothesis. With somewhat more certainty, the two replication studies effectively exclude a direct role for the SNP notwithstanding the circumstantial support that it may affect the splicing of an mRNA expressed in brain regions relevant to schizophrenia.
DISC1 expression via anti-sense RNA. Interestingly DISC1 and 2 are located close to the chromosome 1 markers implicated in two Finnish linkage studies. There is evidence from basic science that the function of DISC1 might be relevant to schizophrenia. For example, the truncated product in the translocation family might contribute to schizophrenia by affecting neuronal functions dependent upon intact cytoskeleton regulation such as neuronal migration, neurite architecture, and intracellular transport.

While interesting hypotheses, it is important to remember that translocations exert effects on genes other than those directly disrupted. For example, there are several mechanistic reasons by which a translocation can influence the expression of neighbouring genes. Thus, in order to unequivocally implicate DISC1 and/or 2 in the pathogenesis of schizophrenia, it is necessary to identify mutations or polymorphisms that are associated with schizophrenia in another population and are not in linkage disequilibrium with neighbouring genes. Four published studies have attempted to do this. Negative studies were reported by the Edinburgh group who originally identified DISC1 and 2, and by a group who focussed on the 5′ end of the gene in a large Japanese sample. However, positive findings have been reported in a large Finnish sample and in US samples with schizophrenia, schizoaffective disorder, and bipolar disorder.

**BIPOLAR DISORDER**

**Genetic epidemiology**

Family, twin, and adoption studies conducted over the last 20–30 years have provided an impressive and consistent body of evidence supporting the existence of genes determining predisposition to bipolar disorder and show a gradation of risk of mood disorder as the genetic relatedness to a proband diminishes (reviewed in detail in Craddock and Jones). There are methodological impediments to precise quantification, but the approximate lifetime risk of narrowly defined bipolar disorder in relatives of a bipolar proband are: unrelated member of the general population: 0.5–1.5%; first degree relative 5–10% (corresponding to 3–5 LOD); monozygotic co-twin 40–70% (corresponding to 8–10 LOD). Further, relatives of bipolar probands are also at a more modest increased risk of unipolar depression (that is, depressive episodes without mania) of the order of 2–3-fold increase of risk for a first degree relative compared with the general population. Estimates of heritability are high: 89% in a recent hospital register study of 67 twin pairs in the UK and 93% in a population register study of 19 124 same-sex twin pairs in Finland.

Occasional families may exist in which a single gene plays the major role in determining susceptibility, but most bipolar disorder involves the interaction of multiple genes (epistasis) or more complex genetic mechanisms (such as dynamic mutation or imprinting). Analyses using mathematical modelling suggest bipolar susceptibility genes are likely to have modest effect sizes (gene-specific sibling recurrence risk: λs < 2) and this is consistent with findings emerging from molecular genetic studies. Bipolar disorder has not yet received the same degree of intensive study as schizophrenia, but a number of chromosomal regions have been repeatedly implicated in linkage studies and replicable findings have now been reported at some genetic loci.

**Linkage findings in bipolar disorder**

Systematic genome screens have been, and are being, conducted on a variety of sample sets, ranging from large densely affected pedigrees in genetic isolates to large numbers of affected sib pairs. The pattern of findings emerging is consistent with there being no gene of major effect to explain the majority of cases of bipolar disorder but several regions have been implicated repeatedly.

Two meta-analyses have been conducted with bipolar genome scan data. Badner and Gershon found the strongest evidence for susceptibility loci on 13q and 22q when examining seven published genome scans for bipolar disorder. However, the more extensive and detailed meta-analysis of Segurodo et al conducted using the same bin ranking methodology as used in the meta-analysis of schizophrenia scans did not find genome-wide significant evidence for linkage but provided a more modest level of support for regions on chromosomes 9p22.3–21.1, 10q11.21–22.1, 14q24.1–32.12, and regions of chromosome 18. This meta-analysis demonstrated lesser consistency in the findings from bipolar scans than from schizophrenia scans. One likely contributor to this difference is the substantially smaller number of pedigrees that were available for inclusion in the bipolar meta-analysis compared with that for schizophrenia: 370 compared with 1208 for narrowly defined illness, respectively. Another consistent difference is that it has been usual to test a broader range of (non-independent) diagnostic models in bipolar scans which require correction for multiple testing, thus reducing power for a given sample size. A further consistent difference is that a greater proportion of larger, extended pedigrees has been investigated for bipolar disorder than for schizophrenia. This may reflect a difference in the genetic architecture of the disorders. If this is the case and if there was consequently a greater heterogeneity between studies in bipolar disorder this would make detection of consistent signals in meta-analyses more difficult, a particular problem using the bin ranking method.

Four bipolar genome scans were not included in the meta-analysis of Segurodo et al because they included less than 20 genotyped affected individuals (and, hence, failed to meet the predefined inclusion criteria used for study selection). These studies used extended pedigrees and two reported genome-wide significant linkage signals. They are shown in table 1.

Since publication of the meta-analyses several further genome-wide scans in independent samples have been published, with several regions identified that meet genome-wide significant or suggestive criteria for linkage criteria (table 2). Of particular note is the 6q16–q25 region which was not implicated in either meta-analysis but which is supported by one genome-wide significant and three genome-wide suggestive signals, making it one of the best supported regions for bipolar disorder.

In fig 1 we show the regions that have received genome-wide significant support in at least one scan. Of particular note are the 6q16–q25 region mentioned above and the 12q23–q24 region which has two genome scans reporting genome-wide significance and is also supported by linkage analysis in two pedigrees that segregate both bipolar spectrum mood disorder and Darier’s disease (an autosomal dominant skin disease caused by mutations at ATP2A2 which maps at 12q23–q24.1) showing maximum LOD > 4 at markers in this region.

**Gene studies of bipolar disorder**

In contrast to schizophrenia, to date there has not been unambiguous demonstration of a susceptibility gene identified for bipolar disorder by positional cloning. Potentially interesting findings have come from study of functional candidates and most recently investigation of genes first implicated in schizophrenia (some of which map in linkage regions of interest in bipolar disorder). However, none of the findings yet achieve the level of support that dysbindin and NRG1 have received in schizophrenia.
A functional candidate gene that has attracted a great deal of recent interest is *brain derived neurotrophic factor* (*BDNF*).117 *BDNF* is a member of the neurotrophin superfamily. Neurotrophins are synthesised in neurons as proforms that can be cleaved intra- or extracellularly and both their synthesis and secretion depends upon neuronal activity. *BDNF* plays an important role in promoting and modifying growth, development, and survival of neuronal populations and, in the mature nervous system, is involved in activity dependent neuronal plasticity,118 processes that are prominent in the synaptic plasticity hypothesis of mood disorder which focuses on the functional and structural changes induced by stress and antidepressants at the synaptic level. The *BDNF* gene lies on the reverse strand of chromosome 11p13 and encodes a precursor peptide (pro*BDNF*), which is cleaved proteolytically to form the mature protein.119 The 11p13 chromosomal location of *BDNF* has been implicated in some linkage studies of bipolar disorder but not in meta-analyses of linkage studies.

Consistent with the strong evolutionary conservation of the *BDNF* coding sequence across species, only one frequent, non-conservative polymorphism in the human *BDNF* gene has been identified, a single nucleotide polymorphism (SNP) at nucleotide 196 within the 5′ pro*BDNF* sequence that causes an amino acid substitution of valine to methionine at codon 66 (Val66Met). There is cross-species conservation of the precursor portion of pro*BDNF* which is consistent with potential functional importance and it is possible that the common Val66Met polymorphism could itself have a functionally relevant effect by modifying the processing and trafficking of *BDNF*.117

There have been three positive reports using family based association studies of Caucasian bipolar disorder samples of European-American origin and the Val66Met SNP: two are in UK case-control sample.116 In all studies evidence for LD came from both individual SNPs as well as multilocus haplotypes, although there is variation between studies in the SNPs and haplotypes showing LD. No pathologically relevant variant has yet been identified and the biological mechanism remains to be elucidated (see schizophrenia section above). *DAO* has been examined in only one study of bipolar disorder46 which found no evidence of LD. However, *DAO* lies in the 12q23 region of linkage interest (see fig 1) and warrants more thorough study in bipolar disorder.

### Brain derived neurotrophic factor (BDNF)

#### Functional candidates

Functional candidate gene studies depend crucially on the choice of candidates. Inevitably this depends on the current level of understanding of disease pathophysiology. For bipolar disorder, most such studies have focussed on neurotransmitter systems influenced by medications employed in the management of the disorder, namely the dopamine, serotonin, and noradrenaline systems (reviewed in Craddock *et al*).108 Amongst the “traditional” candidates, the genes encoding monoamine oxidase A (MAOA), tyrosine hydroxylase, catecho-<t>l-O-methyltransferase (COMT), and the serotonin transporter (SHTT) have received particularly extensive attention. While the usual pattern for each of these genes has been for some positive studies along with some negative reports, meta-analyses of polymorphisms of known functional relevance in three of the genes are significant at the *p*<0.05 level: MAOA,109 COMT,110 and SHTT,111,112 all with modest effect sizes (odds ratios (OR)=2). It is of interest that COMT has been also been implicated in schizophrenia73 and has received support from the same group in a modestly sized study of bipolar disorder.113 These findings remain to be tested in the independent, large samples that will be required to determine with unambiguously whether and to what extent variation within these genes contributes to susceptibility to bipolar disorder.

Many of the candidate gene reports in the literature describe studies in modestly sized samples (a few hundred individuals). As for all complex disorders, the trend in candidate gene studies of bipolar disorder is for the use of larger samples with increased power to detect modest or small effect sizes and examination of candidate genes predicted on more sophisticated models of pathogenesis or directed by positional information from linkage studies. Replicable positive findings have started to emerge from these approaches over the last 2–3 years.

#### *D*-amino acid oxidase activator DAOA(G72)/G30 locus

At least five independent datasets contribute evidence that variation at the DAOA/G30 locus on chromosome 13q influences susceptibility to bipolar disorder. As described in the schizophrenia sections above, this locus was implicated initially as being involved in susceptibility to schizophrenia. Subsequently linkage disequilibrium at this locus was reported also with bipolar disorder in two US family samples114 and this was replicated in a further US family reported also with bipolar disorder in two US family studies.115 Subsequently linkage disequilibrium at this locus was implicated in influences susceptibility to bipolar disorder. As described in these genes contributes to susceptibility to bipolar disorder.116 Independent, large samples that will be required to determine with more thorough study in bipolar disorder.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Genome scans excluded from meta-analysis because of the small number of genotyped affected individuals (&lt;20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>Sample</td>
</tr>
<tr>
<td>Ewald <em>et al</em>115</td>
<td>Two Danish pedigrees</td>
</tr>
<tr>
<td>Radhakrishna <em>et al</em>116</td>
<td>Large Turkish pedigree</td>
</tr>
<tr>
<td>Adams <em>et al</em>117</td>
<td>Large Australian pedigree</td>
</tr>
<tr>
<td>Blackwood <em>et al</em>118</td>
<td>Large Scottish pedigree</td>
</tr>
</tbody>
</table>

Regions reported as genome-wide significant according to the criteria of Lander and Kruglyak15 are shown in bold. Regions reported as genome-wide suggestive according to the criteria of Lander and Kruglyak are shown in italics.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Bipolar genome scans reported subsequent to the meta-analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>Sample</td>
</tr>
<tr>
<td>Lambert <em>et al</em>119</td>
<td>395 sib pairs in Wellcome Trust stage 2 sample</td>
</tr>
<tr>
<td>Fallin <em>et al</em>120</td>
<td>41 Ashkenazi pedigrees (sibs)</td>
</tr>
<tr>
<td>Middleton <em>et al</em>121</td>
<td>25 Portuguese origin pedigrees</td>
</tr>
<tr>
<td>Dick <em>et al</em>122</td>
<td>250 NIH pedigrees (wave 3)</td>
</tr>
<tr>
<td>Dick <em>et al</em>122, Willour <em>et al</em>123, Zandi <em>et al</em>124</td>
<td>56 NIH pedigrees (wave 2)</td>
</tr>
</tbody>
</table>

Regions reported as genome-wide significant according to the criteria of Lander and Kruglyak15 are shown in bold. Regions reported as genome-wide suggestive according to the criteria of Lander and Kruglyak are shown in italics.

---

*www.jmedgenet.com*
adult bipolar samples and one with a small childhood onset sample. All have shown over-transmission of the common Val allele. Evidence with multilocus haplotypes was stronger in one study. There have been four case-control association studies (of European, Chinese and Japanese origin) to date, in which there is no evidence for an allelic or genotypic association. In our own UK case-control study of close to 1000 bipolar cases we found no significant evidence for association of the Val allele (or multilocus haplotypes) with bipolar disorder but some evidence for association within phenotypic subsets of the data (unpublished data).

Substantial additional genetic and biological work will be required to confirm (or refute) the role of BDNF in influencing susceptibility to bipolar disorder. Systematic study of variation across the whole gene is required with study in further independent samples.

**Other genes**

We will briefly mention three other genes that have recently been reported as “bipolar genes”. Two of these are in the 22q chromosome region of interest: G-protein receptor kinase 3 (GRK3) was implicated through positional follow up of a linkage signal in a set of US pedigrees and was supported also by expression data in a rodent model of mania. However, this has not yet received independent support. XBP1, a pivotal gene in the endoplasmic reticulum (ER) stress response, was reported to show association at a promoter polymorphism with bipolar disorder susceptibility in two small association samples. Some degree of circumstantial biological support for a functional role for this polymorphism came from a cellular model of the action of mood stabiliser medications. However, this report is highly likely to be a type I error because the putative functionally relevant variant was found to have no influence on susceptibility in independent family based and case-control association samples six times larger than those in the initial report. More promisingly, but as yet not widely tested, is the report that P2X7, in the 12q24 region of linkage interest, influences susceptibility to both bipolar disorder and unipolar depression.

**Closer attention to the phenotype: clinical covariates and sub-types**

As discussed elsewhere, bipolar disorder researchers have been taking an interest in a variety of clinical sub-types and covariates over recent years as a way of testing subsets of cases with increased clinical (and hopefully genetic) homogeneity. Examples include rapid cycling (illness characterised by a high recurrence rate—at least four distinct episodes per year), lithium responsiveness, bipolar affective puerperal psychosis (triggering of bipolar episodes in females by parturition), early age at onset, occurrence of psychotic features during illness, and sub-types (of European, Chinese and Japanese origin) to date, in which there is no evidence for an allelic or genotypic association. In our own UK case-control study of close to 1000 bipolar cases we found no significant evidence for association of the Val allele (or multilocus haplotypes) with bipolar disorder but some evidence for association within phenotypic subsets of the data (unpublished data).

Substantial additional genetic and biological work will be required to confirm (or refute) the role of BDNF in influencing susceptibility to bipolar disorder. Systematic study of variation across the whole gene is required with study in further independent samples.

**Other genes**

We will briefly mention three other genes that have recently been reported as “bipolar genes”. Two of these are in the 22q chromosome region of interest: G-protein receptor kinase 3 (GRK3) was implicated through positional follow up of a linkage signal in a set of US pedigrees and was supported also by expression data in a rodent model of mania. However, this has not yet received independent support. XBP1, a pivotal gene in the endoplasmic reticulum (ER) stress response, was reported to show association at a promoter polymorphism with bipolar disorder susceptibility in two small association samples. Some degree of circumstantial biological support for a functional role for this polymorphism came from a cellular model of the action of mood stabiliser medications. However, this report is highly likely to be a type I error because the putative functionally relevant variant was found to have no influence on susceptibility in independent family based and case-control association samples six times larger than those in the initial report. More promisingly, but as yet not widely tested, is the report that P2X7, in the 12q24 region of linkage interest, influences susceptibility to both bipolar disorder and unipolar depression.

**Closer attention to the phenotype: clinical covariates and sub-types**

As discussed elsewhere, bipolar disorder researchers have been taking an interest in a variety of clinical sub-types and covariates over recent years as a way of testing subsets of cases with increased clinical (and hopefully genetic) homogeneity. Examples include rapid cycling (illness characterised by a high recurrence rate—at least four distinct episodes per year), lithium responsiveness, bipolar affective puerperal psychosis (triggering of bipolar episodes in females by parturition), early age at onset, occurrence of psychotic features during illness, and sub-types (of European, Chinese and Japanese origin) to date, in which there is no evidence for an allelic or genotypic association. In our own UK case-control study of close to 1000 bipolar cases we found no significant evidence for association of the Val allele (or multilocus haplotypes) with bipolar disorder but some evidence for association within phenotypic subsets of the data (unpublished data).

Substantial additional genetic and biological work will be required to confirm (or refute) the role of BDNF in influencing susceptibility to bipolar disorder. Systematic study of variation across the whole gene is required with study in further independent samples.

**Twin studies**

Only one twin study has used an analysis that was unconstrained by the diagnostic hierarchy inherent in current classification systems (that is, the principle that schizophrenia “trumps” mood disorder in diagnosis). This study demonstrated a clear overlap in the genetic susceptibility to syndromically defined mania and schizophrenia. The findings suggested the existence of some susceptibility genes that are specific to schizophrenia, others that are specific to bipolar disorder, and yet others that influence susceptibility to schizoaffective disorder, schizophrenia, and bipolar disorder. A particularly graphic illustration of the varied expression of the same set of susceptibility genes is provided by the Maudsley triplets—a set of genetically identical triplets, two of whom had a lifetime diagnosis of schizophrenia and the third a lifetime diagnosis of bipolar disorder.

**Linkage studies**

As indicated above, genetic linkage studies have identified some chromosome regions that show convergent or overlapping regions of interest in both disorders, including regions of 13q, 22q, 18, and 6q (fig 1). There are, however, difficulties in interpreting overlaps in linkage findings from different phenotypes because of the poor localisation of linkage signals for complex disorders and the consequent difficulty of measuring co-localisation of signals and assessing statistical evidence for significant co-occurrence. However, the hypothesis that loci exist that influence susceptibility across the schizophrenia-bipolar divide receives further support from the observation that a genome scan using families ascertained on the basis of a proband with schizoaffective disorder (a form of illness with prominent features of both schizophrenia and bipolar disorder) demonstrated genome-wide significance at 1q42 and suggestive linkage at 22q11, with linkage evidence being contributed equally from “schizophrenia” families (that is, where other members had predominantly schizophrenia) and
“bipolar families” (that is, where other members had predominantly bipolar disorder).156

**Gene studies**

Most persuasively, several recent reports implicate variation at the same loci as influencing susceptibility to both schizophrenia and bipolar disorder.

**G72(DAOA)/G30**

Currently the best supported locus for bipolar disorder is G72(DAOA)/G30 on chromosome 13q14.116–14 which also has positive association reported in schizophrenia.166

**DISC1**

The DISC1 locus at 1q42 receives linkage support in both schizophrenia67–69 and bipolar disorder166 and, although it has been named “Disrupted in Schizophrenia”, the family in which the translocation was observed contained cases of both psychosis and mood disorder; indeed the formal linkage evidence was actually somewhat greater for mood diagnoses than for psychosis diagnoses.156 Evidence for allelic association at polymorphisms at this locus has been reported for schizophrenia, bipolar disorder, and schizoaffective disorder.156

**NRG1**

Neuregulin 1 is one of the best supported schizophrenia susceptibility genes with several studies showing evidence that a so-called Icelandic “core haplotype” is associated with increased risk in Icelandic, Scottish, and UK populations.12–14 We have found that this same haplotype is significantly associated with risk for bipolar disorder and that it may exert a specific effect in the subset of functional psychosis that has both manic and mood incongruent psychotic features.156 Further support for the role of NRG1 across the mood-psychosis spectrum comes from a Dutch sample in which variation at NRG1 was found to influence susceptibility only to the subset of schizophrenia cases with predominantly good outcome.156 This is the subset that typically has more features in common with mood disorders.

**COMT**

We have discussed the COMT locus in relation to both schizophrenia and bipolar disorder. It lies at 22q11, a region implicated in both disorders.13 It is extremely likely that genetic variation in this region influences susceptibility across the psychosis spectrum, although it is not yet clear that COMT itself is the (or the major) susceptibility gene at this locus (see discussion in schizophrenia section).

These gene findings provide strong evidence that, as suggested by the family and twin data, there are genetic loci that contribute susceptibility across the Kraepelinian divide to schizophrenia, bipolar disorder, and schizoaffective disorders. These findings have important implications for classification of the major psychiatric disorders because they demonstrate an overlap in the biological basis of disorders that have, over the last 100 years, been classified as distinct entities.156 Thus, we can expect that over the coming years molecular genetics will catalyse a re-appraisal of psychiatric nosology as well as providing a path to understanding the pathophysiology that will facilitate development of improved treatments. For example, current genetic findings suggest that rather than classifying psychosis as a dichotomy, a more useful formulation may be to conceptualise a spectrum of clinical phenotype with susceptibility conferred by overlapping sets of genes.156 Already it is possible to recognise some common biological features amongst the genes implicated by current studies and tentative models have been advanced that postulate the key role of synaptic function.156

In the past psychiatric genetics has often attracted the pessimistic view that it is an area of endeavour that is so complex that advances were unlikely. However, the heritabilities of the major psychiatric disorders—schizophrenia and bipolar disorder—are amongst the highest of human illnesses. To place it in perspective, they are similar to that of height164 and type 1 diabetes,162 163 and greater than breast cancer,164 coronary heart disease in males,165 and type II diabetes.166 Moreover, in the last 2–3 years findings have been accruing (table 3) that will allow psychiatric genetics to take its place amongst the more successful areas of complex human disease genetics.

These developments can be expected to continue. This will change the practice of clinical psychiatry and have enormous potential to benefit our patients.

**ACKNOWLEDGEMENTS**

The authors are indebted to all the individuals who have participated in our studies.

**Authors’ affiliations**

N Craddock, M C O’Donovan, M J Owen, Department of Psychological Medicine, The Henry Wellcome Building for Biomedical Research in Wales, Wales School of Medicine, Cardiff University, Health Park, Cardiff, CF14 4XN, UK

The authors are grateful for support for their research in the genetics of schizophrenia and bipolar disorder to the UK Medical Research Council and the Wellcome Trust

Competing interests: none declared

**REFERENCES**


---

Table 3 Summary of current weight of evidence supporting several of the more promising genes implicated in the pathogenesis of schizophrenia and/or bipolar disorder

<table>
<thead>
<tr>
<th>Gene/Locus</th>
<th>Chromosomal location</th>
<th>Evidence in schizophrenia</th>
<th>Evidence in bipolar disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysbindin</td>
<td>6p22</td>
<td>++++</td>
<td></td>
</tr>
<tr>
<td>NRG1</td>
<td>8p12</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>DISC1</td>
<td>1q42</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>ROS1</td>
<td>1q23</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>COMT</td>
<td>22q11</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>DAOA(G72)/G30</td>
<td>13q33</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>BDNF</td>
<td>11p13</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>DAO</td>
<td>12q23</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

More + symbols indicate greater evidence. The scale is relative.
The genetics of schizophrenia and bipolar disorder


human gene G72 and the gene for D-amino acid oxidase in schizophrenia.


65 De Blasi A, Caron PJ, Pin J, Nicoletti F. Molecular determinants of


Genetics of schizophrenia and bipolar disorder


The genetics of schizophrenia and bipolar disorder: dissecting psychosis

N Craddock, M C O'Donovan and M J Owen

doi: 10.1136/jmg.2005.030718

Updated information and services can be found at:
http://jmg.bmj.com/content/42/3/193

These include:

References
This article cites 153 articles, 25 of which you can access for free at:
http://jmg.bmj.com/content/42/3/193#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/